Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities[1].
Penpulimab demonstrates better stability and a lower level of host-cell protein residue compared with IgG4 backbone anti-PD-1 antibodies[1].
Penpulimab does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) and induces no remarkable IL-6 and IL-8 release by activated macrophages[1].
Penpulimab exhibits slower binding off-rate for human PD-1 than Nivolumab and Pembrolizumab [1].
Penpulimab potentiates T cell activation via PD-1/PD-L1 blockade[1].
Penpulimab (5 mg/kg; i.p.; twice a week, 3weeks) inhibits tumor growth in mice[2].
| Animal Model: | MC38-hPD-L1 tumor-bearing B-hPD-1 humanized mouse model[2] |
| Dosage: | 5 mg/kg |
| Administration: | IP, twice a week, 3weeks |
| Result: | Showed moderate inhibition of tumor growth (tumor volume: 58.4% of control group). Treatment combined with anlotinib (1 mg/kg, every day, p.o) significantly decreased tumor volume to 36.5% of control group. |